Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025
We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...
The Healthcare Sector and its Dynamics in the Stock Market
We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...
Inhibikase Therapeutics appoints Mark Iwicki as CEO
Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
BioSpace2d
I&I Investment Ramps Up With Novel Targets and Boundless Opportunity
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc.
labiotech6d
Seven companies using metabolomics to decode biology
Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.